Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 5,022	$ 9,276
Accounts receivable	13	32
Prepaid expenses and other current assets	688	441
Mortgage note receivable, current portion	213	170
Total current assets	5,936	9,919
Property and equipment, net	357	430
Deposits	56	31
Mortgage note receivable, long-term portion	2,303	2,354
In process research and development	146,301	146,301
Goodwill	65,195	65,195
Total assets	220,148	224,230
Current liabilities:
Accounts payable and accrued expenses	1,514	2,585
Derivative liabilities	1,869	4,115
Total current liabilities	3,383	6,700
Long-term liabilities
Deferred rent	57	61
Deferred tax liability	49,875	49,875
Total long-term liabilities	49,932	49,936
Total liabilities	53,315	56,636
Stockholders' equity:
Common stock, $.001 par value; 800,000 shares authorized; 704,255 and 694,396 issued and outstanding as of June 30, 2016 and December 31, 2015, respectively	704	694
Additional paid-in capital	235,924	229,456
Accumulated deficit	(69,795)	(62,556)
Total stockholders' equity	166,833	167,594
Total liabilities and stockholders' equity	220,148	224,230
Series A Convertible Preferred Stock
Commitments and contingencies
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, 0 shares issued and outstanding at June 30, 2016 and December 31, 2015 respectively, issued in the merger with RFS Pharma, LLC
Stockholders' equity:
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 0 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively
Series B Convertible Preferred Stock
Commitments and contingencies
Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, 0 shares issued and outstanding at June 30, 2016 and December 31, 2015 respectively, issued in the merger with RFS Pharma, LLC
Stockholders' equity:
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 0 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively